Renaissance Investment Group LLC Sells 413 Shares of Danaher Co. (NYSE:DHR)

Renaissance Investment Group LLC lowered its stake in Danaher Co. (NYSE:DHR) by 0.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 50,315 shares of the conglomerate’s stock after selling 413 shares during the period. Danaher makes up 2.9% of Renaissance Investment Group LLC’s holdings, making the stock its 12th biggest holding. Renaissance Investment Group LLC’s holdings in Danaher were worth $13,988,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of DHR. GLOBALT Investments LLC GA bought a new position in Danaher in the fourth quarter valued at about $320,000. Beacon Financial Group acquired a new stake in shares of Danaher during the fourth quarter valued at about $233,000. Chicago Partners Investment Group LLC boosted its stake in shares of Danaher by 10.0% during the fourth quarter. Chicago Partners Investment Group LLC now owns 9,994 shares of the conglomerate’s stock valued at $2,285,000 after purchasing an additional 907 shares in the last quarter. Centaurus Financial Inc. boosted its stake in shares of Danaher by 2.1% during the fourth quarter. Centaurus Financial Inc. now owns 6,153 shares of the conglomerate’s stock valued at $1,423,000 after purchasing an additional 127 shares in the last quarter. Finally, Pineridge Advisors LLC acquired a new stake in shares of Danaher during the fourth quarter valued at about $74,000. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other Danaher news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares in the company, valued at $27,435,240. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock worth $11,042,433 in the last quarter. 11.10% of the stock is currently owned by company insiders.

Danaher Trading Up 1.5 %

Shares of Danaher stock opened at $270.33 on Friday. The stock has a fifty day simple moving average of $270.31 and a 200 day simple moving average of $259.20. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70. The company has a market capitalization of $200.23 billion, a P/E ratio of 45.82, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.05 EPS. On average, sell-side analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a $0.27 dividend. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Analyst Ratings Changes

DHR has been the topic of a number of recent research reports. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. The Goldman Sachs Group lifted their price objective on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Stifel Nicolaus lifted their price objective on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. Bank of America lifted their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Finally, Barclays lifted their price objective on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $282.12.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.